Ventrazym is an ongoing hard science project studying methodologies of moving the digestive therapy to the stomach and the impact this has on patient Quality Of Life.
We aim to generate a continuous body of publications.
Besides its impact on the science community view of PERT, these will be used for fine-tuning and refinement of the formulation.
Ventrazym is an ongoing hard science project studying methodologies of moving the digestive therapy to the stomach and the impact this has on patient Quality Of Life.
We aim to generate a continuous body of publications.
Besides its impact on the science community view of PERT, these will be used for fine-tuning and refinement of the formulation.
Ventrazym is an ongoing hard science project studying methodologies of moving the digestive therapy to the stomach and the impact this has on patient Quality Of Life.
We aim to generate a continuous body of publications.
Besides its impact on the science community view of PERT, these will be used for fine-tuning and refinement of the formulation.
Mechanical Innovation
Mechanical Innovation
Using enzymes from multiple sources with different pH activity, we ensure that the product has a wide pH activity covering the entire digestive system.
Peak pH Activity
We ensure that there is always some of the enzymes in their peak pH activity. Some enzymes will have peak activity at pH 2.5, some at 4.5. While the pH activity range is from 2 to 10.
Peak pH Activity
We ensure that there is always some of the enzymes in their peak pH activity. Some enzymes will have peak activity at pH 2.5, some at 4.5. While the pH activity range is from 2 to 10.
Peak pH Activity
We ensure that there is always some of the enzymes in their peak pH activity. Some enzymes will have peak activity at pH 2.5, some at 4.5. While the pH activity range is from 2 to 10.
Reduced Intestinal Work
Starting the digestive aid in the stomach delivers the food already digested to the intestine.
Reduced Intestinal Work
Starting the digestive aid in the stomach delivers the food already digested to the intestine.
Reduced Intestinal Work
Starting the digestive aid in the stomach delivers the food already digested to the intestine.
Using enzymes from multiple sources with different pH activity, we ensure that the product has a wide pH activity covering the entire digestive system.
Using enzymes from multiple sources with different pH activity, we ensure that the product has a wide pH activity covering the entire digestive system.
Scientific Board
Scientific Board
Ventrazym research project Scientific Board unites world-class medical authorities to steward the rigorous validation of VentraZym. Through their strategic oversight, we are establishing the market’s most comprehensive evidence base for alternative PERT.
Our Scientific Board unites world-class medical authorities to steward the rigorous validation of VentraZym. Through their strategic oversight, we are establishing the market’s most comprehensive evidence base for alternative PERT.
Our Scientific Board unites world-class medical authorities to steward the rigorous validation of VentraZym. Through their strategic oversight, we are establishing the market’s most comprehensive evidence base for alternative PERT.
Clinical Studies & Publications
Clinical Studies & Publications
The Ventrazym project aims to produce constant publications to change the reality of PERT and enhance patient quality of life today rather than in the far future.
We aim to become the most studied alternative PERT on the market, with an evolving formulation based on the studies.
Although VentraZym was launched in September, we have already finalised a study in the Gastro Labs (Uppsala University), a study at the University of Athens, and a study at the Food and Agricultural University of Athens.
Our studies will be made public once published. For a copy untill then, please reach out to Ventrazym@milltons.com.
Publications about reducing symptoms by moving PERT to the stomach:
Publications about reducing symptoms by moving PERT to the stomach:
Publications about reducing symptoms by moving PERT to the stomach:
Belgium- 2003- University Hospital Gasthuisberg
Summary: In this small crossover trial of CF children on high-dose pancrelipase, adding a PPI (omeprazole) halved fecal fat losses and significantly raised fat absorption (87%→94%). By using omeprazole, the stomach and duodenal pH were raised, so the supplied enzymes remained active when released. The improved fat absorption suggests that any enzyme activity preserved in the upper gut (even near the stomach) was beneficial.
Belgium- 2003- University Hospital Gasthuisberg
Summary: In this small crossover trial of CF children on high-dose pancrelipase, adding a PPI (omeprazole) halved fecal fat losses and significantly raised fat absorption (87%→94%). By using omeprazole, the stomach and duodenal pH were raised, so the supplied enzymes remained active when released. The improved fat absorption suggests that any enzyme activity preserved in the upper gut (even near the stomach) was beneficial.
Belgium- 2003- University Hospital Gasthuisberg
Summary: In this small crossover trial of CF children on high-dose pancrelipase, adding a PPI (omeprazole) halved fecal fat losses and significantly raised fat absorption (87%→94%). By using omeprazole, the stomach and duodenal pH were raised, so the supplied enzymes remained active when released. The improved fat absorption suggests that any enzyme activity preserved in the upper gut (even near the stomach) was beneficial.
Italy- 2023-University of Napoli Federico II
Summary: Randomized, double-blind, placebo-controlled trial of 120 adults with functional dyspepsia, supplementation with a multi-enzyme blend significantly reduced upper GI symptom severity and improved quality of life and sleep scores compared with placebo over 2 months.
Italy- 2023-University of Napoli Federico II
Summary: Randomized, double-blind, placebo-controlled trial of 120 adults with functional dyspepsia, supplementation with a multi-enzyme blend significantly reduced upper GI symptom severity and improved quality of life and sleep scores compared with placebo over 2 months.
Italy- 2023-University of Napoli Federico II
Summary: Randomized, double-blind, placebo-controlled trial of 120 adults with functional dyspepsia, supplementation with a multi-enzyme blend significantly reduced upper GI symptom severity and improved quality of life and sleep scores compared with placebo over 2 months.
China- 2009- Department of Gastroenterology, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Summary: multicenter randomized, placebo-controlled crossover study conducted in China, 151 adults with functional dyspepsia were treated with a digestive enzyme combination active in the stomach. It significantly reduced overall dyspepsia severity.
China- 2009- Department of Gastroenterology, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Summary: multicenter randomized, placebo-controlled crossover study conducted in China, 151 adults with functional dyspepsia were treated with a digestive enzyme combination active in the stomach. It significantly reduced overall dyspepsia severity.
China- 2009- Department of Gastroenterology, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Summary: multicenter randomized, placebo-controlled crossover study conducted in China, 151 adults with functional dyspepsia were treated with a digestive enzyme combination active in the stomach. It significantly reduced overall dyspepsia severity.
USA- 2016- Department of Medicine, Baylor College of Medicine, Houston, TX
This 2016 narrative review concludes that pancreatic enzyme replacement therapy (PERT) formulated to be active in the stomach or proximal duodenum may reduce pain in “some” chronic pancreatitis patients by restoring CCK-mediated negative feedback and lowering pancreatic stimulation. Further research is recommended.
USA- 2016- Department of Medicine, Baylor College of Medicine, Houston, TX
This 2016 narrative review concludes that pancreatic enzyme replacement therapy (PERT) formulated to be active in the stomach or proximal duodenum may reduce pain in “some” chronic pancreatitis patients by restoring CCK-mediated negative feedback and lowering pancreatic stimulation. Further research is recommended.
USA- 2016- Department of Medicine, Baylor College of Medicine, Houston, TX
This 2016 narrative review concludes that pancreatic enzyme replacement therapy (PERT) formulated to be active in the stomach or proximal duodenum may reduce pain in “some” chronic pancreatitis patients by restoring CCK-mediated negative feedback and lowering pancreatic stimulation. Further research is recommended.
India- 2018 - Bangalore
In this 2018 randomized, double-blind, placebo-controlled trial conducted over 40 adults with functional dyspepsia were randomized to receive a multienzyme complex (MEC) active in the stomach or placebo for 60 days. Significantly greater improvements in multiple dyspepsia symptom scores were noted.
India- 2018 - Bangalore
In this 2018 randomized, double-blind, placebo-controlled trial conducted over 40 adults with functional dyspepsia were randomized to receive a multienzyme complex (MEC) active in the stomach or placebo for 60 days. Significantly greater improvements in multiple dyspepsia symptom scores were noted.
India- 2018 - Bangalore
In this 2018 randomized, double-blind, placebo-controlled trial conducted over 40 adults with functional dyspepsia were randomized to receive a multienzyme complex (MEC) active in the stomach or placebo for 60 days. Significantly greater improvements in multiple dyspepsia symptom scores were noted.
The Ventrazym project aims to produce constant publications to change the reality of PERT and enhance patient quality of life today rather than in the far future.
We aim to become the most studied alternative PERT on the market, with an evolving formulation based on the studies.
Although VentraZym was launched in September, we have already finalised a study in the Gastro Labs (Uppsala University), a study at the University of Athens, and a study at the Food and Agricultural University of Athens.
Our studies will be made public once published. For a copy untill then, please reach out to ventrazym@milltons.com.
The Ventrazym project aims to produce constant publications to change the reality of PERT and enhance patient quality of life today rather than in the far future.
We aim to become the most studied alternative PERT on the market, with an evolving formulation based on the studies.
Although VentraZym was launched in September, we have already finalised a study in the Gastro Labs (Uppsala University), a study at the University of Athens, and a study at the Food and Agricultural University of Athens.
Our studies will be made public once published. For a copy untill then, please reach out to Ventrazym@milltons.com.